Загрузка...
Realized and Projected Cost-Savings from the Introduction of Generic Imatinib Through Formulary Management in Patients with Chronic Myelogenous Leukemia
BACKGROUND: Imatinib, a first-generation tyrosine kinase inhibitor (TKI), and the newer second-generation TKIs have dramatically improved outcomes for patients with chronic myelogenous leukemia (CML). A previous model estimated the potential cost-savings over the next 2 years after the loss of paten...
Сохранить в:
| Опубликовано в: : | Am Health Drug Benefits |
|---|---|
| Главные авторы: | , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Engage Healthcare Communications, LLC
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6996618/ https://ncbi.nlm.nih.gov/pubmed/32055281 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|